Trial Profile
A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Effectiveness and Safety of AZD2066 After 6 Weeks of Treatment in Patients With Major Depressive Disorder - D0475C00020.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Oct 2012
Price :
$35
*
At a glance
- Drugs AZD 2066 (Primary) ; Duloxetine
- Indications Major depressive disorder
- Focus Therapeutic Use
- 04 Jan 2011 Planned End Date changed from 1 Jan 2011 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 15 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 Jun 2010 New trial record